BCL2 and hematologic disorder: In several studies, the anti-apoptotic BCL2 protein was overexpressed in MCS; therefore, BCL2 inhibitors, e.g., Venetoclax used in hematological malignancies treatment [52], may be a promising target in MCS treatment [33,57,61].